



Targeted Strategies for Today's Evolving Markets



[Home](#)
[About Us](#)
[Blog](#)
[Clients](#)
[Conferences](#)
[IR Services](#)
[Market Research](#)
[Partners](#)
[Contact](#)

MissionIR Blog

CytRx Corp. (CYTR) Price Rally, Potential Mirrors Pharmacyclics (PCYC) Performance

Posted on [December 13, 2013](#) by [MissionIR](#)

It's quite a catching opener, especially if you're an investor with an interest in the biotech sector. It's also a bold statement, though one backed by weighty evidence. In an article published today, Wall Street Cheat Sheet contributor James Ratz begins with:

"The biggest story this week in biotechnology has been the explosion seen in shares of CytRx Corporation (NASDAQ:CYTR). In fact, the recent move catapults CytRx to one of the top performing biotechnology stocks of 2013, and what's really interesting is that based on the recent news, CytRx may be on the verge of altering the cancer landscape ..."

Comparing CytRx' rally to a previous one stunted by Pharmacyclics (PCYC), Ratz combs through the reasons both companies' ability to apply treatment to several diseases.

To read the full article visit: <http://wallstcheatsheet.com/stocks/is-cytrx-corporation-the-next-pharmacyclics.html>

CytRx is developing aldoxorubicin as a potential alternative to the commonly used chemotherapeutic agent doxorubicin. Aldoxorubicin's primary application is for soft tissue sarcoma, followed by a variety of other cancers including glioblastoma multiforme and Kaposi's sarcoma.

The company recently released the results of its ongoing phase 2b clinical trial in which aldoxorubicin met primary and secondary endpoints, boasting 80-100 percent superiority over doxorubicin in progression-free survival (PFS).

Adding to the obvious potential of these results, Ratz suggests that CytRx could be the "next Pharmacyclics" for three primary reasons:

- Platform applicable to multiple diseases
- "Smart Money" purchasing shares
- Sudden share price explosion

The article summarizes Pharmacyclics' developments and its stock's tremendous bull run started in 2011, as well as provides supporting evidence for Ratz's assessment before concluding that:

"The similarities between CytRx and Pharmacyclics are hard to ignore. A world class platform that has the potential to cure millions and generate billions, a significant institutional interest, and a rapid share price explosion, all lend credence to the theory that CytRx may soon follow a similar path to Pharmacyclics. Dr. Gene Salkind and the other institutions on board are likely adding to their already massive holdings as I write this article, hoping that this run is just getting started."

For more information visit www.cytrx.com

Let us hear your thoughts below:

This entry was posted in [CytRx Corp. CYTR](#), [Small Cap News](#). Bookmark the [permalink](#).



[Home](#)
[About Us](#)
[Blog](#)
[Clients](#)
[Conferences](#)
[IR Services](#)
[Market Research](#)
[Partners](#)
[Contact](#)
[Disclaimer](#)

© 2014 Mission Investor Relations All rights reserved. 3645 Marketplace Blvd, Suite 130-280 Atlanta, GA 30344 404-941-8975

Mission Investor Relations is an affiliate network partner of [DreamTeamGroup](#). Please read [Disclaimers](#) for FULL Compensation Disclosures and other disclaimers.

